Level 1 - Absolute Beginner

Pancreatic cancer is a very serious disease. It is hard to treat. Most patients do not live very long after the doctor finds it.

A new drug called daraxonrasib helped patients live longer. Instead of 6.6 months, patients lived 13.2 months. This is nearly two times longer.

Doctors from around the world heard this news at a big meeting. They were very happy. Some of them stood and clapped.

The drug comes in a pill. Patients can take it at home. This is easier than going to a hospital for treatment.

cancer

a disease where cells in the body grow out of control and can spread to other parts

drug

a medicine used to treat or prevent illness

patient

a person who receives medical care or treatment

trial

a test to find out if a medicine is safe and helpful for people

survival

staying alive despite a serious illness or danger

pill

a small solid medicine that you swallow whole

treatment

the medical care given to a patient to help them get better

months

units of time, with 12 months in one year

Level 2 - Elementary

A new oral drug called daraxonrasib has nearly doubled the survival time for patients with advanced pancreatic cancer, according to results from a major clinical trial presented at the American Society of Clinical Oncology meeting in Chicago in late May 2026. Patients who took the drug lived for a median of 13.2 months, compared to just 6.6 months for those who received standard chemotherapy.

Pancreatic cancer is one of the most deadly forms of cancer because it is usually found at a late stage and does not respond well to most treatments. The survival rate has barely improved in decades. That is why the results from the RASolute 302 trial were described as a breakthrough.

Daraxonrasib works by targeting a gene mutation called RAS, which is found in nearly all pancreatic cancer cells. By blocking the mutated RAS protein, the drug prevents cancer cells from growing and dividing. This approach is called a targeted therapy because it attacks a specific weakness in the cancer cell rather than harming all cells as chemotherapy does.

The drug is taken once a day as an oral tablet. This is more convenient than traditional intravenous chemotherapy, which requires regular hospital visits and takes hours to administer. Revolution Medicines, the company that makes daraxonrasib, is working with the US Food and Drug Administration to accelerate its approval for wider use.

oral drug

a medicine that is taken by mouth and swallowed

clinical trial

a carefully designed study that tests whether a new medicine is safe and effective in people

median

the middle value in a set of numbers, used in medicine to describe typical survival time

chemotherapy

a type of cancer treatment using powerful drugs to destroy cancer cells

gene mutation

a change in the DNA code that can affect how cells grow and function

targeted therapy

a cancer treatment that attacks specific molecules involved in cancer cell growth

intravenous

delivered directly into a vein using a needle or tube

breakthrough

a sudden important discovery or achievement that changes the course of a field

Level 3 - Intermediate

Results from the Phase 3 RASolute 302 clinical trial, presented by lead investigator Dr Brian Wolpin at the American Society of Clinical Oncology 2026 annual meeting in Chicago on May 31, demonstrated that daraxonrasib, an investigational oral RAS inhibitor developed by Revolution Medicines, nearly doubled median overall survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma. Participants who received daraxonrasib achieved a median overall survival of 13.2 months compared with 6.6 months for those on standard-of-care cytotoxic chemotherapy, representing a hazard ratio of 0.54. The presentation received a standing ovation, a rare occurrence at a medical conference, reflecting the magnitude of the improvement in a disease with a historically grim prognosis.

Pancreatic cancer remains one of the most lethal malignancies. The five-year survival rate across all stages is approximately 13 percent, and for metastatic disease it falls below 3 percent. Progress in the field has been frustratingly slow, with gemcitabine-based regimens offering minimal gains since their approval in the late 1990s. The emergence of a targeted therapy against a mutation as common as KRAS, which drives roughly 90 percent of pancreatic cancers, therefore represents a genuine turning point.

Daraxonrasib belongs to a new class of drugs called RAS inhibitors. Unlike earlier RAS inhibitors that required the protein to be in a specific inactive state, daraxonrasib blocks the protein while it is actively driving cell growth. Revolution Medicines designed the molecule to bind selectively to the active conformation of mutated KRAS, including the KRAS G12D variant that accounts for nearly 40 percent of all KRAS mutations in pancreatic cancer. The drug's oral bioavailability and once-daily dosing schedule represent a significant quality-of-life advantage over intravenous regimens that require long infusion appointments.

The FDA has granted daraxonrasib both Breakthrough Therapy Designation and Orphan Drug Designation, reflecting the agency's recognition of the unmet medical need. An expanded access programme is now available for eligible patients who have already progressed through first-line chemotherapy. Revolution Medicines expects to submit a New Drug Application to the FDA in the second half of 2026, which could lead to formal approval in 2027. If approved, daraxonrasib is likely to become the standard second-line treatment for KRAS-mutated pancreatic cancer, a patient population of approximately 50,000 people in the United States annually.

RAS inhibitor

a drug that blocks the RAS protein that drives cancer cell growth

metastatic pancreatic ductal adenocarcinoma

the most common form of pancreatic cancer that has spread to other organs

hazard ratio

a statistical measure comparing the risk of an event, such as death, between two groups over time

KRAS G12D variant

Level 4 - Advanced

Phase 3 RASolute 302 data, unblinded and presented by Dr Brian Wolpin of the Dana-Farber Cancer Institute at the American Society of Clinical Oncology 2026 plenary session in Chicago on May 31, demonstrate that daraxonrasib, Revolution Medicines' oral covalent RAS multi-selective inhibitor, achieved a median overall survival of 13.2 months versus 6.6 months for standard-of-care second-line chemotherapy in patients with previously treated KRAS-mutated metastatic pancreatic ductal adenocarcinoma, a hazard ratio of 0.54 (95 percent CI: 0.44 to 0.67; p less than 0.0001). Progression-free survival was likewise nearly doubled: 5.1 months versus 2.6 months, HR 0.51. The overall response rate in the daraxonrasib arm was 36 percent versus 12 percent for chemotherapy, with eight patients achieving complete responses. The plenary audience's standing ovation was unprecedented in recent ASCO memory for a pancreatic cancer presentation, reflecting how far these numbers diverge from anything the field has produced in the past two decades.

The mechanistic distinction of daraxonrasib merits elaboration. First-generation KRAS G12C inhibitors, including sotorasib and adagrasib, occupy the switch-II pocket only when KRAS is in its GDP-bound inactive state. KRAS in pancreatic adenocarcinoma exists predominantly in the GTP-bound active state because oncogenic G12D and G12V substitutions impair intrinsic GTPase activity and block GAP-mediated hydrolysis, rendering the protein constitutively active. Revolution Medicines addressed this by designing daraxonrasib as a covalent inhibitor of the active GTP-bound conformation, incorporating a reactive warhead that forms a durable bond with the cysteine residue adjacent to the mutation under physiological conditions. Multi-selectivity across G12D, G12V, G12R, G13D, and other common KRAS variants distinguishes daraxonrasib from its predecessors.

Tolerability was broadly consistent with earlier Phase 1 and 2 data. Rash and stomatitis, manageable with topical corticosteroids and dose modification, were the most common treatment-emergent adverse events leading to dose reduction in the daraxonrasib arm. No treatment-related deaths occurred. Grade 3 to 4 events were reported in 34 percent of the experimental arm versus 51 percent in the chemotherapy arm, suggesting a superior therapeutic index despite the drug's mechanistic novelty. These data, combined with the once-daily oral dosing and ambient-temperature storage requirement, markedly reduce the clinical infrastructure and patient burden compared to FOLFIRINOX or gemcitabine-nab-paclitaxel regimens.

The regulatory and commercial trajectory is rapid. The FDA's Breakthrough Therapy Designation and Orphan Drug Designation, both awarded in 2025, activated rolling review privileges, meaning Revolution Medicines has been submitting NDA modules to the FDA since Q1 2026. The company expects to complete the NDA submission by Q3 2026, targeting a standard 12-month PDUFA review clock that could yield an approval decision as early as Q3 2027. Analysts at SVB Securities and Leerink Partners have modelled peak US revenues of 3.5 to 4.8 billion dollars annually, contingent on first-line label expansion, which requires a positive readout from the ongoing RASolute 301 first-line monotherapy trial expected in Q2 2027.